Compounds > 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
Page last updated: 2024-09-02

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Carcinoma

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione has been researched along with Carcinoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blessing, JA; Homesley, HD; Petty, W; Thigpen, JT1
Blessing, JA; Fowler, WC; Hatch, K; Thigpen, JT1

Trials

1 trial(s) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Carcinoma

ArticleYear
Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Cancer treatment reports, 1986, Volume: 70, Issue:9

    Topics: Carcinoma; Cisplatin; Drug Evaluation; Female; Humans; Neoplasm Recurrence, Local; Piperazines; Uterine Cervical Neoplasms

1986

Other Studies

1 other study(ies) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Carcinoma

ArticleYear
Phase II trial of piperazinedione in the treatment of advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study.
    American journal of clinical oncology, 1986, Volume: 9, Issue:1

    Topics: Adult; Aged; Carcinoma; Drug Evaluation; Female; Humans; Middle Aged; Piperazines; Uterine Neoplasms

1986